Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


S. Korea Report Accuses Generics Makers Of Overpricing

This article was originally published in PharmAsia News

Executive Summary

South Korea's drug authority accused the country's drug makers of inflating the prices of their generic drugs. The Korea Development Institute said in a report that some drug makers sell generics for prices close to the price of the brand-name drug even though the generic makers experienced no development costs. In some cases, it said, the generic price is as close as 80 percent of the brand price. A KDI researcher attributed some of the pricing to government controls that set prices based on hospital negotiations with drug makers who give kickbacks to the hospitals. The reported noted that 80 percent of drugs sold in South Korea are generics. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts